Prevalence and incidence of HIV in a rural community-based HIV vaccine preparedness cohort in Masaka, Uganda
- PMID: 21677779
- PMCID: PMC3108994
- DOI: 10.1371/journal.pone.0020684
Prevalence and incidence of HIV in a rural community-based HIV vaccine preparedness cohort in Masaka, Uganda
Abstract
Background: Local HIV epidemiology data are critical in determining the suitability of a population for HIV vaccine efficacy trials. The objective of this study was to estimate the prevalence and incidence of, and determine risk factors for HIV transmission in a rural community-based HIV vaccine preparedness cohort in Masaka, Uganda.
Methods: Between February and July 2004, we conducted a house-to-house HIV sero-prevalence survey among consenting individuals aged 18-60 years. Participants were interviewed, counseled and asked to provide blood for HIV testing. We then enrolled the HIV uninfected participants in a 2-year HIV sero-incidence study. Medical evaluations, HIV counseling and testing, and sample collection for laboratory analysis were done quarterly. Sexual risk behaviour data was collected every 6 months.
Results: The HIV point prevalence was 11.2%, and was higher among women than men (12.9% vs. 8.6%, P = 0.007). Risk factors associated with prevalent HIV infection for men were age <25 years (aOR = 0.05, 95% CI 0.01-0.35) and reported genital ulcer disease in the past year (aOR = 2.17, 95% CI 1.23-3.83). Among women, being unmarried (aOR = 2.59, 95% CI 1.75-3.83) and reported genital ulcer disease in the past year (aOR = 2.40, 95% CI 1.64-3.51) were associated with prevalent HIV infection. Twenty-one seroconversions were recorded over 2025.8 person-years, an annual HIV incidence of 1.04% (95% CI: 0.68-1.59). The only significant risk factor for incident HIV infection was being unmarried (aRR = 3.44, 95% CI 1.43-8.28). Cohort retention after 2 years was 87%.
Conclusions: We found a high prevalence but low incidence of HIV in this cohort. HIV vaccine efficacy trials in this population may not be feasible due to the large sample sizes that would be required. HIV vaccine preparatory efforts in this setting should include identification of higher risk populations.
Conflict of interest statement
References
-
- UNAIDS/WHO. AIDS epidemic update. Geneva: UNAIDS; 2009.
-
- Vardas E, Buttò S, Glashoff R, Malnati SM, Poli G, et al. Preparing for phase II/III HIV vaccine trials in Africa. Microbes and Infection. 2005;7:1436–1444. - PubMed
-
- Kamali A, Kinsman J, Nalweyiso N, Mitchell K, Kanyesigye E, et al. A community randomized controlled trial to investigate impact of improved STD management and behavioural interventions on HIV incidence in rural Masaka, Uganda: trial design, methods and baseline findings. Tropical Medicine and International Health. 2002;7:1053–1063. - PubMed
-
- Victora GC, Huttly RS, Fuchs CS, Olinto AMT. The Role of Conceptual Frameworks in Epidemiological Analysis: A Hierarchical Approach. International Journal of Epidemiology. 1997;26:224–227. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
